Equities research analysts expect that Cambrex Co. (NYSE:CBM) will post sales of $157.43 million for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Cambrex’s earnings, with the highest sales estimate coming in at $168.04 million and the lowest estimate coming in at $148.39 million. Cambrex posted sales of $141.10 million during the same quarter last year, which would indicate a positive year over year growth rate of 11.6%. The firm is scheduled to issue its next quarterly earnings report on Thursday, May 2nd.
On average, analysts expect that Cambrex will report full-year sales of $649.18 million for the current financial year, with estimates ranging from $641.66 million to $655.22 million. For the next financial year, analysts forecast that the business will post sales of $663.69 million, with estimates ranging from $656.84 million to $672.70 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Cambrex.
Cambrex (NYSE:CBM) last announced its quarterly earnings data on Wednesday, February 13th. The biotechnology company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.32 by $0.12. The business had revenue of $212.30 million during the quarter, compared to analysts’ expectations of $182.49 million. Cambrex had a net margin of 17.37% and a return on equity of 14.74%. The business’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.26 EPS.
Several equities analysts have recently weighed in on CBM shares. TheStreet lowered shares of Cambrex from a “b” rating to a “c+” rating in a report on Monday, December 3rd. Zacks Investment Research lowered shares of Cambrex from a “buy” rating to a “hold” rating in a report on Tuesday, February 12th. ValuEngine lowered shares of Cambrex from a “sell” rating to a “strong sell” rating in a report on Wednesday, December 26th. Finally, Jefferies Financial Group lowered shares of Cambrex from a “buy” rating to a “hold” rating and set a $43.00 target price for the company. in a report on Friday, February 22nd. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $48.75.
In related news, CFO Gregory Sargen sold 5,802 shares of the business’s stock in a transaction on Friday, February 15th. The shares were sold at an average price of $37.45, for a total value of $217,284.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Shawn Cavanagh sold 6,769 shares of the business’s stock in a transaction on Friday, February 15th. The stock was sold at an average price of $37.60, for a total transaction of $254,514.40. The disclosure for this sale can be found here. 1.41% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of CBM. American Century Companies Inc. purchased a new stake in shares of Cambrex during the fourth quarter worth $261,000. Geode Capital Management LLC grew its holdings in shares of Cambrex by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 353,011 shares of the biotechnology company’s stock worth $13,329,000 after buying an additional 26,856 shares in the last quarter. Norges Bank purchased a new stake in shares of Cambrex during the fourth quarter worth $12,632,000. Nordea Investment Management AB grew its holdings in shares of Cambrex by 3.1% during the fourth quarter. Nordea Investment Management AB now owns 69,215 shares of the biotechnology company’s stock worth $2,614,000 after buying an additional 2,071 shares in the last quarter. Finally, APG Asset Management N.V. purchased a new stake in shares of Cambrex during the fourth quarter worth $512,000.
Shares of NYSE:CBM traded up $0.66 during trading on Thursday, hitting $39.26. 286,937 shares of the stock traded hands, compared to its average volume of 444,401. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.93 and a quick ratio of 2.86. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of 14.17, a price-to-earnings-growth ratio of 3.42 and a beta of 2.42. Cambrex has a 52-week low of $33.80 and a 52-week high of $69.43.
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Further Reading: New Google Finance Tool and Screening Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.